Positron Emission Tomography, Positron Emission Tomography-Computed Tomography, and Molecular Imaging of the Breast Cancer Patient

Seminars in Roentgenology

Volumn 42, Issue 4, 2007, Pages 265-279

  Franc, Benjamin L ^a   Hawkins, Randall A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; 3' FLUOROTHYMIDINE; ANTHRACYCLINE; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; TETRAFOSMIN TC 99M; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EQUIPMENT; HUMAN; IMAGING SYSTEM; METASTASIS; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TECHNIQUE; TREATMENT RESPONSE;

BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASS SCREENING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34848854774     PISSN: 0037198X     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ro.2007.06.005     Document Type: Article

References (112)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Smigal C., Jemal A., Ward E., et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56 (2006) 168-183
3. Nuyten D.S., Kreike B., Hart A.A., et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8 (2006) R62
4. Beyer T., Townsend D.W., Brun T., et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 41 (2000) 1369-1379
5. Andrieux A., Switsers O., Chajari M.H., et al. Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients. A comparative study between dedicated camera and dual-head coincidence gamma camera. Q J Nucl Med Mol Imaging 50 (2006) 68-77
6. Marshall C., Mustafa S., Wheatley D.C., et al. A comparison of 18F-FDG gamma camera PET, mammography and ultrasonography in demonstrating primary disease in locally advanced breast cancer. Nucl Med Commun 25 (2004) 721-725
7. Bar-Shalom R., Guralnik L., Tsalic M., et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 32 (2005) 918-924
8. Kim T.Y., Kim W.B., Ryu J.S., et al. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 115 (2005) 1074-1078
9. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
10. Pelosi E., Messa C., Sironi S., et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 31 (2004) 932-939
11. Brix G., Lechel U., Glatting G., et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 46 (2005) 608-613
12. Wu T.H., Chu T.C., Huang Y.H., et al. A positron emission tomography/computed tomography (PET/CT) acquisition protocol for CT radiation dose optimization. Nucl Med Commun 26 (2005) 323-330
13. Abreu M.C., Almeida P., Balau F., et al. Clear-PEM: a dedicated PET camera for improved breast cancer detection. Radiat Prot Dosimetry 116 (2005) 208-210
14. Rosen E.L., Turkington T.G., Soo M.S., et al. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology 234 (2005) 527-534
15. Berg W.A., Weinberg I.N., Narayanan D., et al. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. Breast J 12 (2006) 309-323
16. Smith T.A., Sharma R.I., Thompson A.M., et al. Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. J Nucl Med 47 (2006) 1525-1530
17. DeGrado T.R., Baldwin S.W., Wang S., et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42 (2001) 1805-1814
18. DeGrado T.R., Reiman R.E., Price D.T., et al. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43 (2002) 92-96
19. Been L.B., Elsinga P.H., de Vries J., et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol 32 (2006) 39-43
20. Mintun M.A., Welch M.J., Siegel B.A., et al. Breast cancer: PET imaging of estrogen receptors. Radiology 169 (1988) 45-48
21. Zasadny K.R., Tatsumi M., and Wahl R.L. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 30 (2003) 274-280
22. Zasadny K.R., and Wahl R.L. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 189 (1993) 847-850
23. Mavi A., Urhan M., Yu J.Q., et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 47 (2006) 1440-1446
24. Hussain R., and Buscombe J.R. A meta-analysis of scintimammography: an evidence-based approach to its clinical utility. Nucl Med Commun 27 (2006) 589-594
25. Korn R.L., Yost A.M., May C.C., et al. Unexpected focal hypermetabolic activity in the breast: significance in patients undergoing 18F-FDG PET/CT. AJR Am J Roentgenol 187 (2006) 81-85
26. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18 (2000) 3495-3502
27. Surti S., Karp J.S., Popescu L.M., et al. Investigation of time-of-flight benefit for fully 3-D PET. IEEE Trans Med Imaging 25 (2006) 529-538
28. Surti S., Karp J.S., and Muehllehner G. Image quality assessment of LaBr3-based whole-body 3D PET scanners: a Monte Carlo evaluation. Phys Med Biol 49 (2004) 4593-4610
29. Povoski S.P., Olsen J.O., Young D.C., et al. Prospective Randomized Clinical Trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol (2006)
30. Takei H., Suemasu K., Kurosumi M., et al. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer. Breast J 12 (2006) S157-S164
31. Badgwell B.D., Povoski S.P., Abdessalam S.F., et al. Patterns of recurrence after sentinel lymph node biopsy for breast cancer. Ann Surg Oncol 10 (2003) 376-380
32. Vanderveen K.A., Schneider P.D., Khatri V.P., et al. Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging. Ann Surg Oncol (2006)
33. Smith I.C., Ogston K.N., Whitford P., et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 228 (1998) 220-227
34. Schirrmeister H., Kuhn T., Guhlmann A., et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28 (2001) 351-358
35. Lovrics P.J., Chen V., Coates G., et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 11 (2004) 846-853
36. Barranger E., Grahek D., Antoine M., et al. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 10 (2003) 622-627
37. Wahl R.L., Siegel B.A., Coleman R.E., et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 22 (2004) 277-285
38. van der Hoeven J.J., Hoekstra O.S., Comans E.F., et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236 (2002) 619-624
39. Kumar R., Chauhan A., Zhuang H., et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 98 (2006) 267-274
40. Crippa F., Gerali A., Alessi A., et al. FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging 31 suppl 1 (2004) S97-S102
41. Gil-Rendo A., Zornoza G., Garcia-Velloso M.J., et al. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93 (2006) 707-712
42. Kumar R., Zhuang H., Schnall M., et al. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 27 (2006) 231-236
43. Chung A., Liou D., Karlan S., et al. Preoperative FDG-PET for axillary metastases in patients with breast cancer. Arch Surg 141 (2006) 783-788 discussion 788-789
44. Lumachi F., Tregnaghi A., Ferretti G., et al. Accuracy of ultrasonography and (99m)Tc-sestamibi scintimammography for assessing axillary lymph node status in breast cancer patients. A prospective study. Eur J Surg Oncol 32 (2006) 933-936
45. Dose J., Bleckmann C., Bachmann S., et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 23 (2002) 857-864
46. Eubank W.B., Mankoff D.A., Vesselle H.J., et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22 (2002) 5-17
47. Bellon J.R., Livingston R.B., Eubank W.B., et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 27 (2004) 407-410
48. Ohta M., Tokuda Y., Suzuki Y., et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 22 (2001) 875-879
49. Gallowitsch H.J., Kresnik E., Gasser J., et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 38 (2003) 250-256
50. Cook G.J., Houston S., Rubens R., et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16 (1998) 3375-3379
51. Cardillo A., De Cicco C., Paganelli G., et al. Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery. Ann Oncol (2006)
52. Buck A., Schirrmeister H., Kuhn T., et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29 (2002) 1317-1323
53. Tran A., Pio B.S., Khatibi B., et al. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. J Nucl Med 46 (2005) 1455-1459
54. Port E.R., Yeung H., Gonen M., et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol 13 (2006) 677-684
55. van Oost F.J., van der Hoeven J.J., Hoekstra O.S., et al. Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography. Eur J Cancer 40 (2004) 1545-1553
56. Isasi C.R., Moadel R.M., and Blaufox M.D. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 90 (2005) 105-112
57. Kamel E.M., Wyss M.T., Fehr M.K., et al. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 129 (2003) 147-153
58. Larcos G., and Maisey M.N. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 17 (1996) 197-198
59. Nakai T., Okuyama C., Kubota T., et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 32 (2005) 1253-1258
60. Abe K., Sasaki M., Kuwabara Y., et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 19 (2005) 573-579
61. Liu Y., Ghesani N., Mirani N., et al. PET-CT demonstration of extensive muscle metastases from breast cancer. Clin Nucl Med 31 (2006) 266-268
62. Luthra K., Shah S., Purandare N., et al. F-18 FDG PET-CT appearance of metastatic brachial plexopathy in a case of carcinoma of the breast. Clin Nucl Med 31 (2006) 432-434
63. Radan L., Ben-Haim S., Bar-Shalom R., et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer (2006)
64. Wolfort R.M., Li B.D., Johnson L.W., et al. The role of whole-body fluorine-18-FDG positron emission tomography in the detection of recurrence in symptomatic patients with stages II and III breast cancer. World J Surg 30 (2006) 1422-1427
65. Santiago J.F., Gonen M., Yeung H., et al. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 50 (2006) 61-67
66. Krak N.C., Hoekstra O.S., and Lammertsma A.A. Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. Eur J Nucl Med Mol Imaging 31 Suppl 1 (2004) S103-S111
67. Eltahir A., Heys S.D., Hutcheon A.W., et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 175 (1998) 127-132
68. Honkoop A.H., van Diest P.J., de Jong J.S., et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77 (1998) 621-626
69. Machiavelli M.R., Romero A.O., Perez J.E., et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4 (1998) 125-131
70. Kim S.J., Kim S.K., Lee E.S., et al. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 15 (2004) 1352-1357
71. McDermott G.M., Welch A., Staff R.T., et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat (2006)
72. Smith I.C., Welch A.E., Hutcheon A.W., et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18 (2000) 1676-1688
73. Schelling M., Avril N., Nahrig J., et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18 (2000) 1689-1695
74. Wahl R.L., Zasadny K., Helvie M., et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11 (1993) 2101-2111
75. Dose Schwarz J., Bader M., Jenicke L., et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 46 (2005) 1144-1150
76. Mankoff D.A., Dunnwald L.K., Gralow J.R., et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 44 (2003) 1806-1814
77. Tseng J., Dunnwald L.K., Schubert E.K., et al. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 45 (2004) 1829-1837
78. Pio B.S., Park C.K., Pietras R., et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8 (2006) 36-42
79. Cachin F., Prince H.M., Hogg A., et al. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 24 (2006) 3026-3031
80. Stafford S.E., Gralow J.R., Schubert E.K., et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 9 (2002) 913-921
81. Mijnhout G.S., Hooft L., van Tulder M.W., et al. How to perform a comprehensive search for FDG-PET literature. Eur J Nucl Med 27 (2000) 91-97
82. Hunter G.J., Hamberg L.M., Alpert N.M., et al. Simplified measurement of deoxyglucose utilization rate. J Nucl Med 37 (1996) 950-955
83. Garcia J.R., Simo M., Soler M., et al. Relative roles of bone scintigraphy and positron emission tomography in assessing the treatment response of bone metastases. Eur J Nucl Med Mol Imaging 32 (2005) 1243-1244
84. Jacene H.A., Ishimori T., Engles J.M., et al. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med 47 (2006) 950-956
85. Engles J.M., Quarless S.A., Mambo E., et al. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med 47 (2006) 603-608
86. Gangloff A., Hsueh W.A., Kesner A.L., et al. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 46 (2005) 1866-1871
87. Kiesewetter D.O., Jagoda E.M., Kao C.H., et al. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl Med Biol 30 (2003) 11-24
88. Dehdashti F., Flanagan F.L., Mortimer J.E., et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26 (1999) 51-56
89. Dehdashti F., Mortimer J.E., Siegel B.A., et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36 (1995) 1766-1774
90. Mankoff D.A., Peterson L.M., Tewson T.J., et al. [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 42 (2001) 679-684
91. Linden H.M., Stekhova S.A., Link J.M., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24 (2006) 2793-2799
92. Dizendorf E.V., Baumert B.G., von Schulthess G.K., et al. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 44 (2003) 24-29
93. Ashamalla H., Rafla S., Parikh K., et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1016-1023
94. Rajendran J.G., Mankoff D.A., O'Sullivan F., et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10 (2004) 2245-2252
95. Kumar R., Chauhan A., Zhuang H., et al. Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography: variations with age, breast density, and menopausal status. Mol Imaging Biol (2006)
96. Vranjesevic D., Schiepers C., Silverman D.H., et al. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med 44 (2003) 1238-1242
97. Hicks R.J., Binns D., and Stabin M.G. Pattern of uptake and excretion of (18)F-FDG in the lactating breast. J Nucl Med 42 (2001) 1238-1242
98. Bhargava P., Glass E., and Ghesani M. Inflammatory F-18 FDG uptake secondary to ruptured breast prosthesis. Clin Nucl Med 31 (2006) 227-228
99. Rousseau C., Bourbouloux E., Campion L., et al. Brown fat in breast cancer patients: analysis of serial (18)F-FDG PET/CT scans. Eur J Nucl Med Mol Imaging 33 (2006) 785-791
100. Jacene H.A., Stearns V., and Wahl R.L. Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clin Nucl Med 31 (2006) 379-381
101. Lucas A.J., Hawkes R.C., Ansorge R.E., et al. Development of a combined microPET-MR system. Technol Cancer Res Treat 5 (2006) 337-341
102. Stadnik T.W., Everaert H., Makkat S., et al. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging-initial findings. Eur Radiol 16 (2006) 2153-2160
103. Heinisch M., Gallowitsch H.J., Mikosch P., et al. Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions. Breast 12 (2003) 17-22
104. Sharma V., Prior J.L., Belinsky M.G., et al. Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med 46 (2005) 354-364
105. Olafsen T., Kenanova V.E., Sundaresan G., et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65 (2005) 5907-5916
106. Zhou D., Carlson K.E., Katzenellenbogen J.A., et al. Bromine- and iodine-substituted 16alpha,17alpha-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity. J Med Chem 49 (2006) 4737-4744
107. Sloka J.S., Hollett P.D., and Mathews M. Cost-effectiveness of positron emission tomography in breast cancer. Mol Imaging Biol 7 (2005) 351-360
108. Tatsumi M., Cohade C., Mourtzikos K.A., et al. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33 (2006) 254-262
109. Fueger B.J., Weber W.A., Quon A., et al. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 7 (2005) 369-376
110. Gennari A., Donati S., Salvadori B., et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 1 (2000) 156-161 discussion 162-163
111. Tiling R., Linke R., Untch M., et al. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. Eur J Nucl Med 28 (2001) 711-720
112. Couturier O., Jerusalem G., N'Guyen J.M., et al. Sequential positron emission tomography using [18F]Fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 12 (2006) 6437-6443